Valuation : Tarsus Pharmaceuticals, Inc.

Market Cap 363.22Cr 312.12Cr 294.02Cr 268.02Cr 501.17Cr 35TCr 503.06Cr 3.48TCr 1.35TCr 18TCr 1.36TCr 1.33TCr 56TCr P/E 2026 *
-38.8x
P/E 2027 * 35.6x
Enterprise Value 363.22Cr 312.12Cr 294.02Cr 268.02Cr 501.17Cr 35TCr 503.06Cr 3.48TCr 1.35TCr 18TCr 1.36TCr 1.33TCr 56TCr EV / Sales 2026 *
5.08x
EV / Sales 2027 * 3.99x
Free-Float
97.13%
Yield 2026 *
-
Yield 2027 * -
1 day-5.10%
1 week+11.78%
Current month+11.49%
1 month+27.75%
3 months+38.78%
6 months+12.98%
Current year+1.09%
1 week 81.07
Extreme 81.07
91.53
1 month 62.85
Extreme 62.85
91.53
Current year 53.89
Extreme 53.89
91.53
1 year 48.2
Extreme 48.2
91.53
3 years 12.57
Extreme 12.57
91.53
5 years 10.8
Extreme 10.8001
91.53
10 years 10.8
Extreme 10.8001
91.53
Manager TitleAgeSince
Chief Executive Officer 48 01/09/2018
Director of Finance/CFO 64 24/04/2023
Chief Tech/Sci/R&D Officer 47 04/11/2024
Director TitleAgeSince
Chairman 48 02/12/2022
Director/Board Member 71 01/12/2019
Director/Board Member 80 01/01/2017
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Sell

Chief Technology Officer

-6,977 0.0159%
02/09/26 Sell

Chief Executive Officer

-10,000 0.0228%
24/04/26 Exercice

Director

2,766 0.0065%
Change 5-day change 1-year change 3-year change Capi.($)
-5.10%+11.78%+45.49%+415.70% 382.75Cr
-0.33%-1.96%+44.63%-2.77% 8.09TCr
-2.05%-0.64%-19.76%-36.79% 6.05TCr
-3.36%-12.10%+446.15%+25.98% 5.6TCr
+0.83%-4.47%-8.40%+30.44% 4.96TCr
-1.11%-6.36%-2.76%+147.94% 4.59TCr
-0.83%-2.46%+49.08%-18.63% 3.14TCr
+1.29%+0.80%+45.58%+96.95% 2.52TCr
-2.00%-3.35%-2.29%+177.79% 2.22TCr
-3.02%-3.10%+60.58%+104.24% 1.66TCr
Average -1.21%+0.62%+65.83%+94.09% 3.92TCr
Weighted average by Cap. -0.63%-0.95%+78.25%+41.92%

Financials

2026 *2027 *
Net sales 71Cr 61Cr 58Cr 53Cr 99Cr 6.8TCr 99Cr 685.25Cr 264.79Cr 3.47TCr 268.33Cr 262.54Cr 11TCr 91Cr 78Cr 74Cr 67Cr 125.6Cr 8.66TCr 126.07Cr 872.57Cr 337.18Cr 4.41TCr 341.68Cr 334.31Cr 14TCr
Net income -9.57Cr -8.23Cr -7.75Cr -7.06Cr -13Cr -910.74Cr -13Cr -92Cr -35Cr -464.14Cr -36Cr -35Cr -1.47TCr 12Cr 9.96Cr 9.38Cr 8.55Cr 16Cr 1.1TCr 16Cr 111.12Cr 43Cr 561.97Cr 44Cr 43Cr 1.78TCr
Net Debt - -
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic.
Employees
370
Date Price Change Volume
09/26/09 $82.77 -5.10% 5,56,804
08/26/08 $87.22 -3.92% 18,18,831
04/26/04 $90.78 +9.10% 15,95,936
03/26/03 $83.21 +0.54% 7,33,746
02/26/02 $82.76 +11.76% 18,99,864
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
82.77USD
Average target price
96.12USD
Spread / Average Target
+16.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TARS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!